Rochester, MN3 Active Studies

Polycystic Kidney Disease Clinical Trials in Rochester, MN

Find 3 actively recruiting polycystic kidney disease clinical trials in Rochester, MN. Connect with local research sites and explore new treatment options.

3
Active Trials
2
Sponsors
280
Enrolling

Recruiting Polycystic Kidney Disease Studies in Rochester

About Polycystic Kidney Disease Clinical Trials in Rochester

Polycystic kidney disease (PKD) is a genetic disorder causing numerous fluid-filled cysts to grow in the kidneys, leading to kidney enlargement and progressive loss of function. Autosomal dominant PKD is the most common form. Treatment includes tolvaptan and management of complications.

There are currently 3 polycystic kidney disease clinical trials recruiting participants in Rochester, MN. These studies are seeking a combined 280 participants. Research is being sponsored by AbbVie, Otsuka Pharmaceutical Development & Commercialization, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Polycystic Kidney Disease Clinical Trials in Rochester — FAQ

Are there polycystic kidney disease clinical trials in Rochester?

Yes, there are 3 polycystic kidney disease clinical trials currently recruiting in Rochester, MN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Rochester?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rochester research site will contact you about next steps.

Are clinical trials in Rochester free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rochester studies also compensate for your time and travel.

What polycystic kidney disease treatments are being tested?

The 3 active trials in Rochester are testing new therapies including novel drugs, biologics, and treatment approaches for polycystic kidney disease.

Data updated March 2, 2026 from ClinicalTrials.gov